ALLO
Price
$1.61
Change
+$0.02 (+1.26%)
Updated
Apr 23 closing price
Capitalization
345.45M
6 days until earnings call
FATE
Price
$1.33
Change
-$0.04 (-2.92%)
Updated
Apr 23 closing price
Capitalization
157.01M
6 days until earnings call
Ad is loading...

ALLO vs FATE

Header iconALLO vs FATE Comparison
Open Charts ALLO vs FATEBanner chart's image
Allogene Therapeutics
Price$1.61
Change+$0.02 (+1.26%)
Volume$2.18M
Capitalization345.45M
Fate Therapeutics
Price$1.33
Change-$0.04 (-2.92%)
Volume$2.16M
Capitalization157.01M
ALLO vs FATE Comparison Chart
Loading...
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALLO vs. FATE commentary
Apr 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALLO is a Hold and FATE is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 24, 2025
Stock price -- (ALLO: $1.61 vs. FATE: $1.34)
Brand notoriety: ALLO and FATE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALLO: 40% vs. FATE: 81%
Market capitalization -- ALLO: $345.45M vs. FATE: $157.01M
ALLO [@Biotechnology] is valued at $345.45M. FATE’s [@Biotechnology] market capitalization is $157.01M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALLO’s FA Score shows that 0 FA rating(s) are green whileFATE’s FA Score has 1 green FA rating(s).

  • ALLO’s FA Score: 0 green, 5 red.
  • FATE’s FA Score: 1 green, 4 red.
According to our system of comparison, FATE is a better buy in the long-term than ALLO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALLO’s TA Score shows that 4 TA indicator(s) are bullish while FATE’s TA Score has 5 bullish TA indicator(s).

  • ALLO’s TA Score: 4 bullish, 5 bearish.
  • FATE’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, FATE is a better buy in the short-term than ALLO.

Price Growth

ALLO (@Biotechnology) experienced а +15.00% price change this week, while FATE (@Biotechnology) price change was +27.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.04%. For the same industry, the average monthly price growth was -8.89%, and the average quarterly price growth was -12.57%.

Reported Earning Dates

ALLO is expected to report earnings on Aug 06, 2025.

FATE is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+8.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALLO($345M) has a higher market cap than FATE($157M). FATE YTD gains are higher at: -19.091 vs. ALLO (-24.413). FATE has higher annual earnings (EBITDA): -176.58M vs. ALLO (-243.33M). ALLO (292M) and FATE (279M) have equal amount of cash in the bank . FATE has less debt than ALLO: FATE (85.3M) vs ALLO (90.8M). FATE has higher revenues than ALLO: FATE (13.6M) vs ALLO (22K).
ALLOFATEALLO / FATE
Capitalization345M157M220%
EBITDA-243.33M-176.58M138%
Gain YTD-24.413-19.091128%
P/E RatioN/AN/A-
Revenue22K13.6M0%
Total Cash292M279M105%
Total Debt90.8M85.3M106%
FUNDAMENTALS RATINGS
ALLO vs FATE: Fundamental Ratings
ALLO
FATE
OUTLOOK RATING
1..100
827
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
18
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9494
PRICE GROWTH RATING
1..100
8147
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
41n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FATE's Valuation (18) in the Biotechnology industry is significantly better than the same rating for ALLO (97). This means that FATE’s stock grew significantly faster than ALLO’s over the last 12 months.

FATE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ALLO (100). This means that FATE’s stock grew similarly to ALLO’s over the last 12 months.

FATE's SMR Rating (94) in the Biotechnology industry is in the same range as ALLO (94). This means that FATE’s stock grew similarly to ALLO’s over the last 12 months.

FATE's Price Growth Rating (47) in the Biotechnology industry is somewhat better than the same rating for ALLO (81). This means that FATE’s stock grew somewhat faster than ALLO’s over the last 12 months.

FATE's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ALLO (100). This means that FATE’s stock grew similarly to ALLO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALLOFATE
RSI
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
76%
MACD
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 1 day ago
83%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 3 days ago
85%
Declines
ODDS (%)
Bearish Trend 17 days ago
88%
Bearish Trend 24 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PGWIX9.79N/A
N/A
Principal MidCap Growth Inst
RYUIX59.03N/A
N/A
Rydex Utilities Inv
HCMIX24.50N/A
N/A
HCM Tactical Growth I
FIKHX107.61N/A
N/A
Fidelity Advisor Technology Z
TVLRX10.92N/A
N/A
Touchstone Value R6

ALLO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALLO has been loosely correlated with CRSP. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if ALLO jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALLO
1D Price
Change %
ALLO100%
+1.26%
CRSP - ALLO
60%
Loosely correlated
-1.76%
FATE - ALLO
55%
Loosely correlated
-2.55%
NTLA - ALLO
55%
Loosely correlated
-2.65%
CRBU - ALLO
51%
Loosely correlated
+0.79%
PRME - ALLO
51%
Loosely correlated
+4.14%
More

FATE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with ALLO. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then ALLO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
-2.55%
ALLO - FATE
55%
Loosely correlated
+1.26%
NTLA - FATE
55%
Loosely correlated
-2.65%
CRBU - FATE
52%
Loosely correlated
+0.79%
CRSP - FATE
50%
Loosely correlated
-1.76%
RXRX - FATE
48%
Loosely correlated
-0.89%
More